These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Sustaining treatment costs: who will pay? Zewdie D; De Cock K; Piot P AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744 [No Abstract] [Full Text] [Related]
5. Balancing effectiveness and access to HIV treatment in the developing world. Hill A; Wood E AIDS; 2007 Jan; 21(3):361-3. PubMed ID: 17255743 [No Abstract] [Full Text] [Related]
6. The cost of antiretroviral drugs and influence on prescribing policies. Jones R; Gazzard B Int J STD AIDS; 2006 Aug; 17(8):499-506. PubMed ID: 16925892 [TBL] [Abstract][Full Text] [Related]
7. Costs associated with combination antiretroviral therapy in HIV-infected patients. Yazdanpanah Y J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277 [TBL] [Abstract][Full Text] [Related]
11. The ethics of AIDS care. Harvey JC J Int Assoc Physicians AIDS Care; 1997 Nov; 3(11):14-24. PubMed ID: 11364809 [TBL] [Abstract][Full Text] [Related]
12. South Africa will not pay for antiretroviral therapy. Sidley P BMJ; 2001 Jun; 322(7300):1441. PubMed ID: 11408289 [No Abstract] [Full Text] [Related]
13. The HIV pharmacy: managing quality and costs of HIV care. Valenti WM AIDS Read; 2002 Nov; 12(11):486-8. PubMed ID: 12498153 [No Abstract] [Full Text] [Related]
14. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options. Over M; Marseille E; Sudhakar K; Gold J; Gupta I; Indrayan A; Hira S; Nagelkerke N; Rao AS; Heywood P Sex Transm Dis; 2006 Oct; 33(10 Suppl):S145-52. PubMed ID: 17003679 [TBL] [Abstract][Full Text] [Related]
15. A train wreck on board the Titanic. Senak M J Int Assoc Physicians AIDS Care; 1996 Jul; 2(7):40-1. PubMed ID: 11363745 [TBL] [Abstract][Full Text] [Related]
16. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. Pinheiro Edos S; Antunes OA; Fortunak JM Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246 [TBL] [Abstract][Full Text] [Related]
17. The impact of highly active antiretroviral combination therapy in HIV infected patients in Glasgow. Fox R; Gourlay YJ Health Bull (Edinb); 2000 Jul; 58(4):309-15. PubMed ID: 12813810 [TBL] [Abstract][Full Text] [Related]
18. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. Hofmann WP; Soriano V; Zeuzem S Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206 [TBL] [Abstract][Full Text] [Related]
19. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973 [TBL] [Abstract][Full Text] [Related]
20. [How to balance the antiretrovirus drugs and cost in China]. Li TS Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1153-4. PubMed ID: 22882999 [No Abstract] [Full Text] [Related] [Next] [New Search]